SCHEMBL5049673

SCHEMBL5049673

Cc1ccc(CNc2cc(C(O)C=Cc3ccc(C(=O)O)c(O)c3)cc3c2C(C)(C)CCC3(C)C)cc1

nearest known ligand 0.44

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
RARA P10276 5/20 0.44
RARB P10826 5/20 0.44
RARG P13631 4/20 0.44
PLK1 P53350 1/20 0.35
HNF4A P41235 2/20 0.34
PTPN1 P18031 1/20 0.33
RXRA P19793 4/20 0.33
GNRHR P30968 1/20 0.32
STAT3 P40763 1/20 0.32
CTDSP1 Q9GZU7 1/20 0.32
SIRT5 Q9NXA8 1/20 0.32
RAB9A P51151 1/20 0.32
CYP26A1 O43174 1/20 0.31
CYP26B1 Q9NR63 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5049669 1.00 RARA (0.44) RARARARBRARGPLK1HNF4A
SCHEMBL5049667 1.00 RARA (0.44) RARARARBRARGPLK1HNF4A
SCHEMBL5044009 0.93 RARA (0.43) RARARARBRARGHNF4APTPN1
SCHEMBL5044015 0.93 RARA (0.43) RARARARBRARGHNF4APTPN1
SCHEMBL5044004 0.93 RARA (0.43) RARARARBRARGHNF4APTPN1
SCHEMBL5050777 0.92 RARA (0.42) RARARARBRARGPLK1HNF4A
SCHEMBL5043992 0.91 RARA (0.42) RARARARBRARGPTPN1RXRA
SCHEMBL5043988 0.91 RARA (0.42) RARARARBRARGPTPN1RXRA
SCHEMBL5044002 0.91 RARA (0.42) RARARARBRARGPTPN1RXRA
SCHEMBL5048384 0.88 RARB (0.58) RARARARBRARGHNF4ARXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7326803-B2 Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-02-05 US claimed
US-20050148670-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-07-07 US claimed
US-7326803-B2 Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-02-05 US disclosed
US-20050148670-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148670-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof RARA, RARB, RARG RARA 1/4885RARB 2/4885RARG 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.